Federated Investors Inc. PA lessened its stake in shares of SAGE Therapeutics Inc (NASDAQ:SAGE) by 84.0% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 5,399 shares of the biopharmaceutical company’s stock after selling 28,271 shares during the quarter. Federated Investors Inc. PA’s holdings in SAGE Therapeutics were worth $845,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of the company. CIBC Asset Management Inc boosted its position in shares of SAGE Therapeutics by 26.4% in the 2nd quarter. CIBC Asset Management Inc now owns 1,633 shares of the biopharmaceutical company’s stock worth $256,000 after purchasing an additional 341 shares in the last quarter. Prudential Financial Inc. boosted its position in shares of SAGE Therapeutics by 9.5% in the 1st quarter. Prudential Financial Inc. now owns 4,220 shares of the biopharmaceutical company’s stock worth $680,000 after purchasing an additional 366 shares in the last quarter. Principal Financial Group Inc. boosted its position in shares of SAGE Therapeutics by 3.2% in the 1st quarter. Principal Financial Group Inc. now owns 12,406 shares of the biopharmaceutical company’s stock worth $1,998,000 after purchasing an additional 382 shares in the last quarter. Neuberger Berman Group LLC boosted its position in shares of SAGE Therapeutics by 15.3% in the 1st quarter. Neuberger Berman Group LLC now owns 3,459 shares of the biopharmaceutical company’s stock worth $557,000 after purchasing an additional 459 shares in the last quarter. Finally, Amalgamated Bank boosted its position in shares of SAGE Therapeutics by 9.2% in the 1st quarter. Amalgamated Bank now owns 5,623 shares of the biopharmaceutical company’s stock worth $906,000 after purchasing an additional 476 shares in the last quarter.

SAGE has been the subject of a number of recent analyst reports. Cowen reissued a “buy” rating and issued a $207.00 price objective on shares of SAGE Therapeutics in a research report on Thursday, June 14th. BidaskClub cut SAGE Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, July 27th. Canaccord Genuity reissued a “buy” rating and issued a $220.00 price objective on shares of SAGE Therapeutics in a research report on Tuesday, June 12th. Morgan Stanley raised their price objective on SAGE Therapeutics from $225.00 to $228.00 and gave the stock an “overweight” rating in a research report on Friday, July 13th. Finally, LADENBURG THALM/SH SH initiated coverage on SAGE Therapeutics in a research report on Wednesday, June 6th. They issued a “buy” rating and a $230.00 price objective for the company. Two equities research analysts have rated the stock with a sell rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $199.19.

Shares of SAGE stock opened at $146.01 on Monday. The firm has a market capitalization of $6.81 billion, a P/E ratio of -20.59 and a beta of 2.90. SAGE Therapeutics Inc has a 1 year low of $59.57 and a 1 year high of $195.97.

SAGE Therapeutics (NASDAQ:SAGE) last issued its earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.84) by $1.48. The firm had revenue of $90.00 million during the quarter. analysts forecast that SAGE Therapeutics Inc will post -7.37 earnings per share for the current fiscal year.

SAGE Therapeutics Company Profile

Sage Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system disorders. Its lead product candidate comprises brexanolone, a proprietary intravenous formulation of allopregnanolone that has completed III clinical trials for the treatment of post-partum depression (PPD).

Read More: Hedge Funds – Risk or Reward?

Institutional Ownership by Quarter for SAGE Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.